| Company* | Product | Description | Indication | Status (Date) |
| CARDIOVASCULAR | ||||
|
|
||||
| Forbes Medi- | FM-VP4 | Cholesterol-lowering pharmaceutical | High cholesterol | Company received approval to start a Phase I/II trial in the Netherlands (9/24) |
|
| ||||
INFECTION |
||||
|
| ||||
| Genelabs | ¿ |
Vaccine | For prevention of disease caused by the hepatitis E virus | Company started a Phase II trial in Nepal (9/25) |
|
| ||||
| Hollis-Eden | HE2000 | Immune-regulating hormone | HIV | Clinical results showed the drug had a significant effect on multiple genes implicated in inflammation and immune suppression associated with HIV progression to AIDS; the study was conducted in South Africa (9/10) |
|
| ||||
| Tripep AB | GPG | Treatment for HIV | HIV | Phase II results were negative, causing the company to cancel the clinical program (9/17) |
| ||||
MISCELLANEOUS |
||||
|
| ||||
| Alizyme plc | ATL- | 5-HT4 receptor agonist/5-HT3 receptor antagonist | Constipation-predominant irritable bowel syndrome | Company received approval to start a Phase IIb trial in the UK (9/19**) |
| ||||
| Cellegy | Rectogesic | Nitroglycerin | Anal fissures | Company submitted a marketing authorization application in the UK (9/5) |
|
| ||||
| Immtech | DB289 | Oral, anti-infective | African sleeping sickness (trypanosomiasis) | Company began a Phase II study in Angola (9/11) |
|
| ||||
| QLT Inc. | Visudyne | Verteporfin for injection | Occult subfoveal choroidal neovascularization | Companies filed for approval in Europe (9/7); companies filed for approval in Canada (9/10) |
| | ||||
| Notes: | ||||
* Privately held; ** Denotes the date the item ran in BioWorld International. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
LSE = London Stock Exchange; TSE = Toronto Stock Exchange | ||||
To read more on related topics, click on one of the words below.